Close Menu

NEW YORK – Quidel said late on Friday that it has received Emergency Use Authorization from the US Food and Drug Administration for the Sofia 2 Flu + SARS Antigen FIA, a rapid, point-of-care test for the qualitative detection and differentiation of SARS-CoV-2 and influenza A/B.

According to Quidel, the assay is the first rapid antigen test for detecting all three viruses simultaneously to receive EUA.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.